Daniel Zandberg

20PUBLICATIONS
141CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsOther biomedical and clinical sciences not elsewhere classifiedChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Apr 01, 2026
Systemic Treatment of Thyroid Cancer: ASCO Guideline.

Nabil F Saba, Nofisat Ismaila, Douglas Adkins

|Mar 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Aarti Bhatia, Zhengjia Chen, Yuji Zhang

|Jan 16, 2026
Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

Martina Chirra, Andrew Elliott, Hira Shaikh

|Dec 04, 2025
Reply to: Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials.

Robert L Ferris, Julie E Bauman, Hong Wang

|Nov 03, 2025
Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.

Seka Lazare, Zhuosheng Gu, Noah Earland

Pageof 4

Frequent Collaborators

8 joint publications

Robert L Ferris

3 joint publications

Nabil F Saba

2 joint publications

Mark W Kubik

2 joint publications

Nassim Morsli